Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name Suzhou Suncadia Biopharmaceuticals Co., Ltd. appears in 20 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
20 shownA Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast CancerNCT07679360 · lead sponsor · 2026-09-02
RECRUITINGA Multicenter, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-6914 Injection in Participants With Prostate CancerNCT07735377 · lead sponsor · 2026-08-26
RECRUITINGA Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung CancerNCT07489716 · lead sponsor · 2026-04-29
RECRUITINGPhase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung CancerNCT07170995 · lead sponsor · 2025-10-22
RECRUITINGA Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast CancerNCT07111832 · lead sponsor · 2025-08-20
RECRUITINGA Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLCNCT06754930 · lead sponsor · 2025-02-18
RECRUITINGAn Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.NCT07863167 · lead sponsor · 2026-10-30
NOT_YET_RECRUITINGThe Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung CancerNCT07704645 · lead sponsor · 2026-08-01
NOT_YET_RECRUITINGA Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLCNCT07183189 · lead sponsor · 2025-10-30
ACTIVE_NOT_RECRUITINGA Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung CancerNCT07009457 · lead sponsor · 2025-06-16
ACTIVE_NOT_RECRUITINGA Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLCNCT06671379 · lead sponsor · 2024-11-29
ACTIVE_NOT_RECRUITINGClinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLCNCT06434103 · lead sponsor · 2024-10-10
WITHDRAWNNeoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer PatientsNCT06592625 · lead sponsor · 2024-09-20
UNKNOWNA Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.NCT05845138 · lead sponsor · 2023-07-25
UNKNOWNPhase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung CancerNCT05503888 · lead sponsor · 2022-10-01
NOT_YET_RECRUITINGPhase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung CancerNCT05416775 · lead sponsor · 2022-08-15
UNKNOWNA Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast CancerNCT05134194 · lead sponsor · 2022-01-17
TERMINATEDA Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-CancerNCT05132413 · lead sponsor · 2021-12-30
UNKNOWNStudy of SHR-1701 Plus BP102 in Subjects With Selected Solid TumorsNCT04974957 · lead sponsor · 2021-08-30
UNKNOWNA Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLCNCT06177925 · collaborator · 2023-12-10
UNKNOWNSponsor roles
lead sponsor19
collaborator1
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.